UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 496 - 510 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Beyond the Abstract - Effect of Tolterodine on Sleep Structure Modulated by CYP2D6 Genotype
Thursday, 06 December 2007
BERKELEY, CA (UroToday.com) - Our new study1 presents a novel genotyping analysis of data recorded in two previous studies on the effect of tolterodine on sleep in healthy sleepers2,3. In the previous studies we have found a significant decrease of REM sleep when applying single doses of tolterodine compared to placebo2.
Login to read more...

Botulinum Toxin A (Botox((R))) Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Literature Review - Abstract
Thursday, 06 December 2007
Hôpital Sainte Marguerite, Marseille, France
read more

Effects of Oxybutynin Transdermal System on Health-Related Quality of Life and Safety in Men with Overactive Bladder and Prostate Conditions - Abstract
Tuesday, 04 December 2007
Weill Medical College of Cornell University, New York, NY, USA
read more

Structure-Activity Studies of Novel Cyanoguanidine ATP-Sensitive Potassium Channel Openers for the Treatment of Overactive Bladder - Abstract
Monday, 03 December 2007
Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064-6104
read more

BJUI Mini-Reviews - November 2007 - Treating Patients with Overactive Bladder Syndrome with Antimuscarinics: Heart Rate Considerations
Thursday, 29 November 2007
Login to read more...

A Role of Intravesical Capsaicin Instillation in Benign Prostatic Hyperplasia with Overactive Bladder Symptoms: The First Reported Study in the Literature - Abstract
Friday, 16 November 2007
Division of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok 10700, Thailand
read more

Does Tolterodine Extended Release Affect the Bladder Electrical Perception Threshold? A Placebo Controlled, Double-Blind Study With 4 and 8 mg in Healthy Volunteers - Abstract
Tuesday, 13 November 2007
Neurourology Department, Spinal Cord Injury Center, Balgrist University Hospital, Zürich, Switzerland.
read more

AUA NY Section 2007 - The Evolution of the Midurethral Sling
Monday, 12 November 2007
Presented on November 12, 2007 at the 2007 Annual Meeting of the New York Section of the AUA in Buenos Aires, Argentina.
Login to read more...

Darifenacin Treatment of Patients ≥ 65 Years with Overactive Bladder: Results of a Randomized, Controlled, 12-Week Trial - Abstract
Monday, 12 November 2007
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Hallam University, UK
read more

The Relative Importance of Health Related Quality of Life and Prescription Insurance Coverage in the Decision to Pharmacologically Manage Symptoms of Overactive Bladder - Abstract
Friday, 09 November 2007
Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia
read more

Anticholinergic Drugs Versus Other Medications for Overactive Bladder Syndrome in Adults - Abstract
Friday, 09 November 2007
Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia
read more

Novel uses for Antidiuresis - Abstract
Thursday, 08 November 2007
Bristol Urological Institute, Southmead Hospital, Westbury on Trym, Bristol, UK
read more

Voiding Urges Perceived by Patients with Interstitial Cystitis/Painful Bladder Syndrome - Abstract
Thursday, 08 November 2007
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
read more

A Prospective Randomised Double-Blind Controlled Trial Evaluating the Effect of Trans-Sacral Magnetic Stimulation in Women with Overactive Bladder - Abstract
Wednesday, 07 November 2007
Department of Urogynaecology, Mercy Hospital for Women, Melbourne, Australia
read more

Nocturia in Women - Abstract
Wednesday, 07 November 2007
Department of Urogynaecology, Kings College Hospital, London, UK
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder